

Serial No.: 08/896,589  
Group Art Unit No.: 1652

47. An isolated polynucleotide comprising a polynucleotide sequence having at least 70% identity over its entire length to a polynucleotide that encodes the polypeptide sequence of SEQ ID NO:2, and which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:1, wherein the percentage identity is calculated by the method of a GCG program.

48. An isolated polynucleotide of claim 47 comprising a polynucleotide sequence having at least 80% identity over its entire length to a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2 and which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:1.

49. An isolated polynucleotide of claim 47 comprising a polynucleotide sequence having at least 90% identity over its entire length to a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2 and which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:1.

50. A polynucleotide encoding a fusion polypeptide having at least 70% identity over its entire length to the amino acid sequence set forth in SEQ ID NO:2 wherein said fusion polypeptide comprises the amino acid sequence of SEQ ID NO:2, wherein the percentage identity is calculated by the method of a GCG program.

51. A polynucleotide which is complementary to a polynucleotide of claim 21 through 50.

#### REMARKS

Support for the new claims may be found, for example, in the specification on pages 6-10, 13-24, and 36. The new claims are directed to the invention in Group I (Claims 1-10) and introduce no new matter.

Serial No.: 08/896,589  
Group Art Unit No.: 1652

The applicants have canceled claims 1-20 without prejudice or disclaimer of the subject matter therein. Claims 11-20 are canceled in response to the 9-way restriction requirement imposed by the Examiner by telephone call of May 14, 1998. Applicants elected to prosecute the claims of Group I (Claims 1-10) without traverse. The Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims and any other claims supported by the specification. Any amendments made herein to the claims were made to solely expedite or otherwise facilitate prosecution and were not made nor should they be construed to have been made to overcome any issue of unpatentability of the claims as the claims existed prior to such amendments.

By the present amendments, claims 21-51, directed to group I, are presented. For fee calculation purposes claim 51 creates fees for 30 claims. Accordingly, the amendments present, for fee purposes, 61 claims including 7 independent claims and at least one multiple dependent claim. The fees required are as set forth in the accompanying transmittal letter.

Allowance of the pending new claims is respectfully requested.

Respectfully submitted,



STEPHEN T. FALK  
Attorney for the Applicants.  
Registration No. 36,795  
DECHERT PRICE & RHOADS  
4000 Bell Atlantic Tower  
1717 Arch Street  
Philadelphia, PA 19103-2793

May 26, 1998

Tel.: (215) 994-2488